Shilpa Medicare Ltd shares rose 8% after the successful completion of Phase 1 clinical trials for recombinant human albumin (rHA). This milestone demonstrates rHA's potential as an alternative to plasma-derived serum albumin. The company plans to begin Phase 3 trials by Q4 FY25, with completion expected within 9-12 months, and product approval filings in FY26.